{"title":"Acquired immune tolerance 2.0.","authors":"Qizhi Tang","doi":"10.1016/j.ajt.2025.02.020","DOIUrl":null,"url":null,"abstract":"<p><p>After liver transplantation, some patients spontaneously become tolerant to the graft and can stop immunosuppression while maintaining functional, biochemical, and histological integrity. The rate of spontaneous liver transplantation tolerance varied from 13 to 80%, depending on the time since transplant and eligibility criteria for immunosuppression withdrawal (1). Two recently concluded liver transplantation immunosuppression withdrawal trials, LIFT and OPTIMAL, found a nearly identical rate of tolerance of 16% among a population of extensively screened and selected patients who underwent medically supervised immunosuppression withdrawal (1, 2). Identifying prospective biomarkers of tolerant will help to select tolerant patients for immunosuppression withdrawal and may inform the underlying immunological mechanisms to guide the design of novel tolerogenic regimen.</p>","PeriodicalId":123,"journal":{"name":"American Journal of Transplantation","volume":" ","pages":""},"PeriodicalIF":8.9000,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Transplantation","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.ajt.2025.02.020","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"SURGERY","Score":null,"Total":0}
引用次数: 0
Abstract
After liver transplantation, some patients spontaneously become tolerant to the graft and can stop immunosuppression while maintaining functional, biochemical, and histological integrity. The rate of spontaneous liver transplantation tolerance varied from 13 to 80%, depending on the time since transplant and eligibility criteria for immunosuppression withdrawal (1). Two recently concluded liver transplantation immunosuppression withdrawal trials, LIFT and OPTIMAL, found a nearly identical rate of tolerance of 16% among a population of extensively screened and selected patients who underwent medically supervised immunosuppression withdrawal (1, 2). Identifying prospective biomarkers of tolerant will help to select tolerant patients for immunosuppression withdrawal and may inform the underlying immunological mechanisms to guide the design of novel tolerogenic regimen.
期刊介绍：
The American Journal of Transplantation is a leading journal in the field of transplantation. It serves as a forum for debate and reassessment, an agent of change, and a major platform for promoting understanding, improving results, and advancing science. Published monthly, it provides an essential resource for researchers and clinicians worldwide.
The journal publishes original articles, case reports, invited reviews, letters to the editor, critical reviews, news features, consensus documents, and guidelines over 12 issues a year. It covers all major subject areas in transplantation, including thoracic (heart, lung), abdominal (kidney, liver, pancreas, islets), tissue and stem cell transplantation, organ and tissue donation and preservation, tissue injury, repair, inflammation, and aging, histocompatibility, drugs and pharmacology, graft survival, and prevention of graft dysfunction and failure. It also explores ethical and social issues in the field.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
